Roche and Eli Lilly's Alzheimer's Blood Test Receives FDA Clearance
The U.S. Food and Drug Administration has officially cleared a blood test for Alzheimer’s disease developed by Roche and Eli Lilly. The test can accurately identify biomarkers of Alzheimer’s through a simple blood sample, eliminating the need for expensive brain scans or invasive cerebrospinal fluid tests. This milestone approval will significantly lower the threshold for early diagnosis, enabling millions of high-risk individuals to receive timely intervention.